Genmab — Februar 2017
-
Darzalex var analytiker-darling i 2016
Genmabs knoglemarvskræftmiddel Darzalex var det lægemiddel, som havde størst medvind hos det globale analytikerkorps i løbet af 2016. Til gengæld er et diabetesmiddel fra Novo Nordisk blandt de største tabere på den konto. Det viser en opgørelse fra EvaluatePharma.
(medwatch.dk)
-
Gid det var så vel bibob.

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
